Alefacept in the treatment of psoriatic nail disease: a proof of concept study

J Drugs Dermatol. 2006 Apr;5(4):339-40.

Abstract

Nail psoriasis can be debilitating and as therapeutic options are limited, it can be notoriously difficult to treat. As there are many new medications currently undergoing clinical trials in psoriasis, questions have arisen concerning the effectiveness of these new therapies with regard to psoriatic nail disease. We present the results of a prospective, open-label, proof of concept study to determine the efficacy and safety of alefacept in subjects with moderate to severe nail psoriasis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alefacept
  • Drug Administration Schedule
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Nail Diseases / drug therapy*
  • Prognosis
  • Psoriasis / drug therapy*
  • Recombinant Fusion Proteins / therapeutic use*
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Alefacept